Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia

James R Cerhan, Celine M Vachon, Thomas Matthew Habermann, Stephen Maxted Ansell, Thomas Elmer Witzig, Paul J. Kurtin, Carol A. Janney, Wei Zheng, John D. Potter, Thomas A. Sellers, Aaron R. Folsom

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Our objective in this study was to evaluate whether the use of hormone replacement therapy (HRT) is associated with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). A cohort of 37,220 Iowa women ages 55 to 69 years in 1986 with no history of prior cancer was linked annually to a population-based cancer registry. Through 1998 (13 years of follow-up), 258 incident cases of NHL were identified, including 135 cases of diffuse NHL, 58 cases of follicular NHL, and 31 cases of small lymphocytic NHL. In addition, 63 cases of CLL were identified. Current and former use of HRT (primarily estrogen) and other cancer risk factors were self-reported on the baseline (1986) questionnaire. Compared with never users of HRT at study baseline, current [multivariate relative risk (RR), 1.4; 95% confidence intervals (CIs), 0.9-2.0) but not former (RR, 1.1; 95% CI, 0.8-1.4) users were at increased risk of NHL after adjustment for age and other confounding factors. This association was seen only in nodal NHL [RRcurrent, 1.5 (95% CI, 1.0-2.4); RRformer, 1.1 (95% CI, 0.8-1.6)] and was not apparent for extra-nodal sites. Of the common subtypes, there was a strong positive association with follicular NHL [RRcurrent, 3.3 (95% CI, 1.6-6.9); RRformer, 2.6 (95% CI, 1.4-4.7)], and women who were current users for more than 5 years had the highest risk (RR, 3.9; 95% CI, 1.8-8.6). There was no association with diffuse or small lymphocytic NHL, or with CLL. Most of the follicular NHLs were nodal (88%), and exclusion of extra-nodal sites slightly strengthened the association with HRT. For diffuse NHL, 64% of the cases were nodal, and there was no association of HRT with either nodal or extra-nodal sites. These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL.

Original languageEnglish (US)
Pages (from-to)1466-1471
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume11
Issue number11
StatePublished - Nov 1 2002

Fingerprint

Hormone Replacement Therapy
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Confidence Intervals
Follicular Lymphoma
Neoplasms
Registries
Estrogens

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia. / Cerhan, James R; Vachon, Celine M; Habermann, Thomas Matthew; Ansell, Stephen Maxted; Witzig, Thomas Elmer; Kurtin, Paul J.; Janney, Carol A.; Zheng, Wei; Potter, John D.; Sellers, Thomas A.; Folsom, Aaron R.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 11, No. 11, 01.11.2002, p. 1466-1471.

Research output: Contribution to journalArticle

@article{5ceeddc2293a4635b4bb5c824f510623,
title = "Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia",
abstract = "Our objective in this study was to evaluate whether the use of hormone replacement therapy (HRT) is associated with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). A cohort of 37,220 Iowa women ages 55 to 69 years in 1986 with no history of prior cancer was linked annually to a population-based cancer registry. Through 1998 (13 years of follow-up), 258 incident cases of NHL were identified, including 135 cases of diffuse NHL, 58 cases of follicular NHL, and 31 cases of small lymphocytic NHL. In addition, 63 cases of CLL were identified. Current and former use of HRT (primarily estrogen) and other cancer risk factors were self-reported on the baseline (1986) questionnaire. Compared with never users of HRT at study baseline, current [multivariate relative risk (RR), 1.4; 95{\%} confidence intervals (CIs), 0.9-2.0) but not former (RR, 1.1; 95{\%} CI, 0.8-1.4) users were at increased risk of NHL after adjustment for age and other confounding factors. This association was seen only in nodal NHL [RRcurrent, 1.5 (95{\%} CI, 1.0-2.4); RRformer, 1.1 (95{\%} CI, 0.8-1.6)] and was not apparent for extra-nodal sites. Of the common subtypes, there was a strong positive association with follicular NHL [RRcurrent, 3.3 (95{\%} CI, 1.6-6.9); RRformer, 2.6 (95{\%} CI, 1.4-4.7)], and women who were current users for more than 5 years had the highest risk (RR, 3.9; 95{\%} CI, 1.8-8.6). There was no association with diffuse or small lymphocytic NHL, or with CLL. Most of the follicular NHLs were nodal (88{\%}), and exclusion of extra-nodal sites slightly strengthened the association with HRT. For diffuse NHL, 64{\%} of the cases were nodal, and there was no association of HRT with either nodal or extra-nodal sites. These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL.",
author = "Cerhan, {James R} and Vachon, {Celine M} and Habermann, {Thomas Matthew} and Ansell, {Stephen Maxted} and Witzig, {Thomas Elmer} and Kurtin, {Paul J.} and Janney, {Carol A.} and Wei Zheng and Potter, {John D.} and Sellers, {Thomas A.} and Folsom, {Aaron R.}",
year = "2002",
month = "11",
day = "1",
language = "English (US)",
volume = "11",
pages = "1466--1471",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia

AU - Cerhan, James R

AU - Vachon, Celine M

AU - Habermann, Thomas Matthew

AU - Ansell, Stephen Maxted

AU - Witzig, Thomas Elmer

AU - Kurtin, Paul J.

AU - Janney, Carol A.

AU - Zheng, Wei

AU - Potter, John D.

AU - Sellers, Thomas A.

AU - Folsom, Aaron R.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Our objective in this study was to evaluate whether the use of hormone replacement therapy (HRT) is associated with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). A cohort of 37,220 Iowa women ages 55 to 69 years in 1986 with no history of prior cancer was linked annually to a population-based cancer registry. Through 1998 (13 years of follow-up), 258 incident cases of NHL were identified, including 135 cases of diffuse NHL, 58 cases of follicular NHL, and 31 cases of small lymphocytic NHL. In addition, 63 cases of CLL were identified. Current and former use of HRT (primarily estrogen) and other cancer risk factors were self-reported on the baseline (1986) questionnaire. Compared with never users of HRT at study baseline, current [multivariate relative risk (RR), 1.4; 95% confidence intervals (CIs), 0.9-2.0) but not former (RR, 1.1; 95% CI, 0.8-1.4) users were at increased risk of NHL after adjustment for age and other confounding factors. This association was seen only in nodal NHL [RRcurrent, 1.5 (95% CI, 1.0-2.4); RRformer, 1.1 (95% CI, 0.8-1.6)] and was not apparent for extra-nodal sites. Of the common subtypes, there was a strong positive association with follicular NHL [RRcurrent, 3.3 (95% CI, 1.6-6.9); RRformer, 2.6 (95% CI, 1.4-4.7)], and women who were current users for more than 5 years had the highest risk (RR, 3.9; 95% CI, 1.8-8.6). There was no association with diffuse or small lymphocytic NHL, or with CLL. Most of the follicular NHLs were nodal (88%), and exclusion of extra-nodal sites slightly strengthened the association with HRT. For diffuse NHL, 64% of the cases were nodal, and there was no association of HRT with either nodal or extra-nodal sites. These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL.

AB - Our objective in this study was to evaluate whether the use of hormone replacement therapy (HRT) is associated with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). A cohort of 37,220 Iowa women ages 55 to 69 years in 1986 with no history of prior cancer was linked annually to a population-based cancer registry. Through 1998 (13 years of follow-up), 258 incident cases of NHL were identified, including 135 cases of diffuse NHL, 58 cases of follicular NHL, and 31 cases of small lymphocytic NHL. In addition, 63 cases of CLL were identified. Current and former use of HRT (primarily estrogen) and other cancer risk factors were self-reported on the baseline (1986) questionnaire. Compared with never users of HRT at study baseline, current [multivariate relative risk (RR), 1.4; 95% confidence intervals (CIs), 0.9-2.0) but not former (RR, 1.1; 95% CI, 0.8-1.4) users were at increased risk of NHL after adjustment for age and other confounding factors. This association was seen only in nodal NHL [RRcurrent, 1.5 (95% CI, 1.0-2.4); RRformer, 1.1 (95% CI, 0.8-1.6)] and was not apparent for extra-nodal sites. Of the common subtypes, there was a strong positive association with follicular NHL [RRcurrent, 3.3 (95% CI, 1.6-6.9); RRformer, 2.6 (95% CI, 1.4-4.7)], and women who were current users for more than 5 years had the highest risk (RR, 3.9; 95% CI, 1.8-8.6). There was no association with diffuse or small lymphocytic NHL, or with CLL. Most of the follicular NHLs were nodal (88%), and exclusion of extra-nodal sites slightly strengthened the association with HRT. For diffuse NHL, 64% of the cases were nodal, and there was no association of HRT with either nodal or extra-nodal sites. These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL.

UR - http://www.scopus.com/inward/record.url?scp=0036845580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036845580&partnerID=8YFLogxK

M3 - Article

C2 - 12433728

AN - SCOPUS:0036845580

VL - 11

SP - 1466

EP - 1471

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -